NCT02344550View on ClinicalTrials.gov

Study of GnRH-A [Leuprorelin(Lorelin Depot] Plus Leterozole +/- Everolimus for Premenopausal Women With Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

137

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

October 31, 2018

Study Completion Date

October 31, 2018

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Everolimus(afinitor)

Everolimus 10mg p.o. daily

DRUG

Letrozole

Letrozole 2.5 mg p.o. daily

DRUG

Leuprolide(Lorelin Depot)

Leuprorelin (Lorelin Depot)3.75 mg SC in every 4 weeks

Trial Locations (1)

138-736

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Asan Medical Center

OTHER